Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 13 | 2023 | 156 | 4.500 |
Why?
|
| Rhinitis | 12 | 2023 | 139 | 3.910 |
Why?
|
| Paranasal Sinuses | 5 | 2022 | 60 | 1.690 |
Why?
|
| Nasal Polyps | 6 | 2023 | 52 | 1.390 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 122 | 1.200 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 2022 | 62 | 1.170 |
Why?
|
| Endoscopy | 9 | 2023 | 176 | 1.020 |
Why?
|
| Chronic Disease | 11 | 2023 | 416 | 0.900 |
Why?
|
| Betacoronavirus | 5 | 2020 | 70 | 0.810 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 82 | 0.770 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 85 | 0.770 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 18 | 0.760 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 15 | 0.680 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 186 | 0.630 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 12 | 0.620 |
Why?
|
| Neutrophils | 1 | 2018 | 96 | 0.590 |
Why?
|
| Otolaryngology | 4 | 2021 | 29 | 0.580 |
Why?
|
| Retrospective Studies | 17 | 2023 | 3291 | 0.570 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.560 |
Why?
|
| Aspergillosis | 1 | 2017 | 11 | 0.560 |
Why?
|
| Mucormycosis | 1 | 2017 | 9 | 0.560 |
Why?
|
| Frozen Sections | 1 | 2017 | 13 | 0.560 |
Why?
|
| Humans | 34 | 2023 | 25969 | 0.560 |
Why?
|
| Nose Neoplasms | 3 | 2022 | 40 | 0.540 |
Why?
|
| Middle Aged | 15 | 2023 | 8508 | 0.410 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 34 | 0.370 |
Why?
|
| Adult | 11 | 2023 | 7351 | 0.370 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 28 | 0.340 |
Why?
|
| Simulation Training | 2 | 2020 | 38 | 0.330 |
Why?
|
| Nose | 2 | 2021 | 36 | 0.320 |
Why?
|
| Male | 14 | 2021 | 13984 | 0.310 |
Why?
|
| Female | 14 | 2021 | 14351 | 0.300 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2023 | 21 | 0.290 |
Why?
|
| Internship and Residency | 2 | 2021 | 206 | 0.290 |
Why?
|
| Aged | 10 | 2023 | 8704 | 0.260 |
Why?
|
| Tertiary Care Centers | 3 | 2020 | 62 | 0.250 |
Why?
|
| Mometasone Furoate | 2 | 2022 | 8 | 0.250 |
Why?
|
| Skull Base | 2 | 2023 | 33 | 0.240 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 929 | 0.230 |
Why?
|
| Inflammation | 3 | 2023 | 264 | 0.230 |
Why?
|
| Intracranial Hypertension | 1 | 2023 | 14 | 0.220 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2023 | 15 | 0.220 |
Why?
|
| Olfaction Disorders | 2 | 2021 | 49 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 125 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 42 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 70 | 0.190 |
Why?
|
| Surgical Flaps | 1 | 2021 | 50 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3293 | 0.190 |
Why?
|
| Pandemics | 5 | 2020 | 238 | 0.190 |
Why?
|
| Air Pollutants | 1 | 2021 | 7 | 0.190 |
Why?
|
| Air Pollution | 1 | 2021 | 11 | 0.190 |
Why?
|
| Melanoma | 1 | 2021 | 48 | 0.180 |
Why?
|
| Child | 2 | 2022 | 1226 | 0.180 |
Why?
|
| Professional Role | 1 | 2021 | 33 | 0.180 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 61 | 0.180 |
Why?
|
| Natural Killer T-Cells | 1 | 2020 | 3 | 0.180 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 7 | 0.180 |
Why?
|
| Nasal Surgical Procedures | 2 | 2017 | 10 | 0.180 |
Why?
|
| Nasopharynx | 1 | 2020 | 5 | 0.180 |
Why?
|
| Epistaxis | 1 | 2020 | 9 | 0.180 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 277 | 0.180 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 8 | 0.180 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 16 | 0.180 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.180 |
Why?
|
| Urban Health Services | 1 | 2020 | 12 | 0.180 |
Why?
|
| Airway Management | 1 | 2020 | 15 | 0.180 |
Why?
|
| Smell | 1 | 2020 | 16 | 0.180 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 15 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2020 | 23 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 73 | 0.170 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2020 | 7 | 0.170 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2020 | 5 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 30 | 0.170 |
Why?
|
| Surgeons | 1 | 2021 | 76 | 0.170 |
Why?
|
| Sella Turcica | 1 | 2019 | 4 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 141 | 0.170 |
Why?
|
| Surgical Wound | 1 | 2019 | 9 | 0.170 |
Why?
|
| Carcinoma | 1 | 2020 | 59 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 713 | 0.170 |
Why?
|
| Preoperative Care | 1 | 2020 | 121 | 0.170 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 29 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 54 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 108 | 0.160 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 4 | 0.160 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 102 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 342 | 0.160 |
Why?
|
| Wound Healing | 1 | 2019 | 146 | 0.160 |
Why?
|
| Phenotype | 1 | 2019 | 289 | 0.160 |
Why?
|
| Fibrosis | 1 | 2018 | 26 | 0.160 |
Why?
|
| Telemedicine | 1 | 2020 | 98 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2020 | 211 | 0.150 |
Why?
|
| Young Adult | 3 | 2020 | 1848 | 0.150 |
Why?
|
| Olfactory Nerve | 1 | 2017 | 2 | 0.150 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2017 | 2 | 0.150 |
Why?
|
| Frontal Sinus | 1 | 2017 | 13 | 0.140 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.140 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 43 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 185 | 0.140 |
Why?
|
| Acute Disease | 1 | 2017 | 189 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4661 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2021 | 862 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 485 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 222 | 0.120 |
Why?
|
| Prognosis | 3 | 2021 | 749 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2021 | 1646 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2021 | 48 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 235 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 313 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 324 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 321 | 0.080 |
Why?
|
| Chicago | 2 | 2020 | 841 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 2240 | 0.060 |
Why?
|
| Adolescent | 2 | 2020 | 2062 | 0.060 |
Why?
|
| Encephalocele | 1 | 2023 | 24 | 0.060 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 27 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 42 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 547 | 0.050 |
Why?
|
| Nasal Lavage | 1 | 2021 | 4 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 11 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 11 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2021 | 13 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2021 | 38 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 4 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 31 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2021 | 10 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 161 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2021 | 16 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 93 | 0.050 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 4 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 360 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 326 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 48 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 18 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 19 | 0.040 |
Why?
|
| Inservice Training | 1 | 2020 | 26 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 32 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 13 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 37 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 37 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 75 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 55 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 53 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 33 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 27 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 45 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 176 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 287 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 193 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 166 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 433 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 670 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 169 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2018 | 35 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 298 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 742 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 1361 | 0.040 |
Why?
|
| Cadaver | 1 | 2017 | 367 | 0.030 |
Why?
|
| United States | 1 | 2020 | 1972 | 0.030 |
Why?
|
Papagiannopoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_